Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27919760 | 1.00 | SLC7A5 (0.38) | SLC7A5NOS1NOS3NOS2CA1 | |
| SCHEMBL2367362 | 0.87 | NOS1 (0.33) | SLC7A5NOS1NOS3NOS2CA1 | |
| SCHEMBL10662683 | 0.86 | NOS1 (0.35) | NOS1NOS3NOS2CA12CA14 | |
| SCHEMBL10659347 | 0.86 | NOS1 (0.35) | NOS1NOS3NOS2CA12CA14 | |
| SCHEMBL6950879 | 0.83 | CYP3A4 (0.37) | NOS1NOS3NOS2CA1CA2 | |
| SCHEMBL1926084 | 0.83 | CYP3A4 (0.37) | NOS1NOS3NOS2CA1CA2 | |
| SCHEMBL6954465 | 0.83 | CYP3A4 (0.37) | NOS1NOS3NOS2CA1CA2 | |
| SCHEMBL7367529 | 0.83 | NOS1 (0.33) | NOS1NOS3NOS2 | |
| SCHEMBL919727 | 0.83 | NOS1 (0.46) | SLC7A5NOS1NOS3NOS2CA1 | |
| SCHEMBL311871 | 0.83 | NOS1 (0.46) | SLC7A5NOS1NOS3NOS2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116514679-A | Palladium-catalyzed sp with low-cost and high-efficiency quaternary ammonium nitrate as oxidant 2 And sp (sp) 3 Carbon hydrogen bond alkenylation method | 南京工业大学 | 2023-08-01 | — | — | CN | claimed |
| EP-0204775-A4 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE. | UNIV TROBE (AU) | 1989-10-04 | — | — | EP | claimed |
| EP-0204775-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1986-12-17 | — | — | EP | claimed |
| WO-1986003746-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | LA TROBE UNIVERSITY (AU) | 1986-07-03 | — | — | WO | claimed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| CN-116874515-B | Amino acid-BSH targeted hybrid compound, and preparation method and application thereof | 重庆高硼生物科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20240383942-A1 | WATER-SOLUBLE ALLOPREGNANOLONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | NANJING MINOVA PHARMACEUTICAL CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| CN-116270255-B | High-adhesion composite sodium hyaluronate repair patch and preparation method thereof | 哈尔滨运美达生物科技有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-116270255-B | High-adhesion composite sodium hyaluronate repair patch and preparation method thereof | 哈尔滨运美达生物科技有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-116270255-A | High-adhesion composite sodium hyaluronate repair patch and preparation method thereof | 哈尔滨运美达生物科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116270255-A | High-adhesion composite sodium hyaluronate repair patch and preparation method thereof | 哈尔滨运美达生物科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023040851-A1 | WATER-SOLUBLE ALLOPREGNANOLONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 南京迈诺威医药科技有限公司 | 2023-03-23 | — | — | WO | disclosed |
| WO-2009120999-A2 | USE OF AN ENDOXIFEN PRODRUG FOR TREATMENT OF BREAST CANCER | OLEMA PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-2008066729-A2 | BORONIC ACID CONTAINING COMPOSITIONS | DARA BIOSCIENCES, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2006129120-A9 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006129120-A2 | BENZOTRIAZEPINONE DERIVATIVES | JAMES BLACK FOUNDATION (GB) | 2006-12-07 | — | — | WO | disclosed |
| WO-1990005141-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUKOCYTIC ELASTASE AND COLLAGENASE | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1990-05-17 | — | — | WO | disclosed |
| EP-0204775-A4 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE. | UNIV TROBE (AU) | 1989-10-04 | — | — | EP | disclosed |
| EP-0204775-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1986-12-17 | — | — | EP | disclosed |
| WO-1986003746-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | LA TROBE UNIVERSITY (AU) | 1986-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | SLC7A5 877/4885NOS1 2695/4885NOS3 1613/4885 |
| US-20240383942-A1 | WATER-SOLUBLE ALLOPREGNANOLONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | HSD11B2, HSD11B1, CYP11B2 | SLC7A5 2630/4885NOS1 2479/4885NOS3 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.